Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
IPO Year: 2017
Exchange: NASDAQ
Website: odonate.com
Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In
Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. As of June 30, 2021, Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of June 30, 2021, Odonate had $110.1 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the six months en
Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate is working with clinical sites to transition patients in ongoing tesetaxel studies to appropriate alternative therapies or facilitate continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of March 31, 2021, Odonate had $133.2 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the three months en
25-NSE - Odonate Therapeutics, Inc. (0001717452) (Subject)
8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)
8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)
10-Q - Odonate Therapeutics, Inc. (0001717452) (Filer)
8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)
10-Q - Odonate Therapeutics, Inc. (0001717452) (Filer)
8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)
DEF 14A - Odonate Therapeutics, Inc. (0001717452) (Filer)
10-Q - Odonate Therapeutics, Inc. (0001717452) (Filer)
8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)
Jefferies downgraded Odonate Therapeutics from Buy to Hold and set a new price target of $4.00 from $45.00 previously
Cowen downgraded Odonate Therapeutics from Outperform to Market Perform
SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
SC 13G - Odonate Therapeutics, Inc. (0001717452) (Subject)
SC 13G - Odonate Therapeutics, Inc. (0001717452) (Subject)
SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
SC 13G - Odonate Therapeutics, Inc. (0001717452) (Subject)
SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)
Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The
Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company's previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases. As of September 30, 2021, as reported in its recently filed Form 10-Q, the Company had total stockholders' equity of $71.4 million, or $1.85 per share, based on 38.5 million shares ou
Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In
Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. As of June 30, 2021, Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of June 30, 2021, Odonate had $110.1 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the six months en
Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate is working with clinical sites to transition patients in ongoing tesetaxel studies to appropriate alternative therapies or facilitate continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of March 31, 2021, Odonate had $133.2 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the three months en
NEW YORK--(BUSINESS WIRE)--Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the clinical data package for tesetaxel is unlikely to support FDA approval. Therefore, Odonate is discontinuing the development of tesetaxel and will wind down the operations of the Company. The Company will work with clinical sites to transition patients in ongoing tesetaxel clinical studies to appropriate alternative therapies. “We thank the investigators, study team personnel, and especially the patients and their caregivers for their endeavors to improve treatments for patients with bre
NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020. As of December 31, 2020, Odonate had $157.3 million in cash, compared to $180.5 million as of December 31, 2019. This decrease in cash resulted primarily from cash used in operating activities for the twelve months ended December 31, 2020 of $113.1 million, partially offset by the receipt of $87.4 million of net proceeds from Odonate’s September 2020 underwritten public offering. Odon
NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its Board of Directors to help guide the company as it seeks commercial approval following announcement of positive Phase 3 data from the PROTECTIVE-2 study of plinabulin in combination with pegfilgrastim for protection against chemotherapy-induced neutropenia. “We are delighted to welcome Dr. Vacirca as a member of our Board of Directors, especially given his impressive leadership within the oncology community,” said Dr. Lan Huang, F
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of patients with cancer, today announced that positive results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer (MBC), were presented in an oral presentation at the 2020 San Antonio Breast Cancer Symposium (SABCS). The results were presented by Joyce O’Shaughnessy, M.D., Celebrating Women Chair in Breast Cancer Research, Baylor University Medical Center, Texas Oncology and Chair, Breast Cancer Research, US Oncology, and Co‑Principal Investigator of CONTESSA (ple
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of Cohort 3 of CONTESSA TRIO, which will evaluate tesetaxel monotherapy in approximately 60 non-elderly patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Cohort 3 of CONTESSA TRIO will complement Cohort 2 of CONTESSA TRIO, which is evaluating tesetaxel monotherapy in approximately 60 elderly patients with HER2-negative MBC. Cohorts 2 and 3 of CONTESSA TRIO will expand on results from TOB203
4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
3 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)
4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)